Biofil Chemicals and Pharmaceuticals Limited

NSE BIOFILCHEM.NS

Biofil Chemicals and Pharmaceuticals Limited EBIT for the year ending March 31, 2024: USD 108.72 K

Biofil Chemicals and Pharmaceuticals Limited EBIT is USD 108.72 K for the year ending March 31, 2024, a 6.95% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

Biofil Chemicals and Pharmaceuticals Limited EBIT for the year ending March 31, 2023 was USD 101.66 K, a -26.87% change year over year.
Biofil Chemicals and Pharmaceuticals Limited EBIT for the year ending March 31, 2022 was USD 139.01 K, a -48.15% change year over year.
Biofil Chemicals and Pharmaceuticals Limited EBIT for the year ending March 31, 2021 was USD 268.07 K, a 29.09% change year over year.
Biofil Chemicals and Pharmaceuticals Limited EBIT for the year ending March 31, 2020 was USD 207.66 K, a 95.75% change year over year.

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

NSE: BIOFILCHEM.NS

Biofil Chemicals and Pharmaceuticals Limited

CEO	Mr. Ramesh S. Shah
IPO Date	July 27, 2017
Location	India
Headquarters	11/12, Sector "E"
Employees	26
Sector	Industrials
Industries Petrochemicals Chemicals & Advanced Materials Cleaning Supplies Cosmetics Fertilizers Personal Care Pharmaceuticals Plastics

Description

Biofil Chemicals and Pharmaceuticals Limited engages in the pharmaceutical and chemical businesses primarily in India. The company offers basic drugs and chemicals, such as sodium chloride, potassium chloride, sodium citrate, diethyl carbamazine citrate, ferrous sulphate, dried ferrous sulphate, ferrous fumerate, micro crystalline cellulose, and dicyclomine hydrochloride; and plastic dippers and caps. It also provides job work service for manufacturing of pharmaceuticals. The company was incorporated in 1985 and is based in Indore, India.

Key trends

Past 5 years